

Vaishali Pharma Ltd.

(Formerly known as Vaishali Pharma Pvt. Ltd.)



CORPORATE OFFICE :

706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819 (30 Lines)
Fax: +91-22-2892 8833
E-mail : info@vaishalipharma.com
export@vaishalipharma.com
CIN - U52310MH2008PLC181632

Date: 23.07.2018

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400051.

Dear Sir(s),

Sub: Media Release dated 23.07.2018

NSE Symbol: VAISHALI NSE Series: SM

Enclosed please find the Media Release dated 23.07.2018 which is self-explanatory for your kind perusal and records.

Thanking you,

Yours Sincerely,
For Vaishali Pharma Limited

Khushboo Panchal
Company Secretary & Compliance officer

Encl: a/a

Media Release

Bagged New Orders (for therapeutic usage) in Three key growing markets of Yemen, Papua New Guinea & Iraq – Total order size of approx 200,000 USD

Also received registrations in high Potential markets - Malopin (Amlodipine – Cardiac medication) in Myanmar and Kolosil (Veterinary - Antibiotic) in Kazakhstan

Mumbai, July 23, 2018: Vaishali Pharma Limited (*NSE EMERGE: VAISHALI*), has received new orders from key growing markets of Yemen, Papua New Guinea & Iraq. The total order size from all these new orders is approximately 200,000 USD.

The Company has received these new orders for therapeutic usages. These products have a good demand in the respective local markets. This signifies a momentous achievement and enables the Company to reach out to more and more territories to strengthen its presence in key markets of these regions.

Following are the country wise Therapeutic usages received in different nations:

Sr. No	Country	Therapeutic Usage
1	Yemen	Cardiac, Anti Respiratory Antibiotics Analgesics & Vitamin Supplements
2	Papua New Guinea	Antibiotic
3	Iraq	Antibiotic & Cephalosporin Injections

The Company also received registrations in high potential markets of Myanmar for Malopin (Cardiac medication) in Myanmar and Kazakhstan for Kolosil (Veterinary - Antibiotic).

The Company has over 70 formulation brands being marketed in multiple countries; with dossier in CTD/ACTD format along with its respective bioequivalence. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with their clients. Passionate to be the best, Vaishali Pharma takes pride in what the Company does and strives to deliver products with zero defects.

Management Comment:

Commenting on the recent development, Ms. Priyanka Vasani, Director, Vaishali Pharma Limited said:

"It is a matter of great pride for the Company to receive prestigious orders for therapeutic usage in three key growing markets of Yemen, Papua New Guinea & Iraq. These new orders are in good demand in all the three markets. We also received registrations for high demand products in regulated markets of Myanmar and Kazakhstan.

It is highly advantageous for our Company to do sale of products in these markets and a remarkable achievement which will further help to offer more products in Yemen, Papua New Guinea & Iraq market. This will enhance stronger relations with our clients worldwide. We are confident that with the continued efforts of the entire team, we will be able to achieve many more such orders in the coming future. This is yet another important step towards laying a strong foundation and meeting our desired targets. Our Company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines.

I would like to thank the entire team of 'Vaishali Pharma Ltd.' for their untiring efforts, hard work, sincerity and high dedication."

About Vaishali Pharma Limited:

Incorporated in the year 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 70 formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective

bioequivalence. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai, our offices are also located in Kenya, & Vietnam. Further widening our reach overseas, the Company made a joint venture with D.R. Congo based company. The Company exports to countries like Africa, Kenya, Myanmar, Vietnam, Russia etc.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects.

For more details please visit: www.vaishalipharma.com

For any Investor Relations query, please contact:

Ms. Priyanka Vasani Director Vaishali Pharma Limited Email: org@vaishalipharma.com	Ms. Savli Mangle Bridge Investor Relations Pvt. Ltd. Email: savli@bridge-ir.com
--	--

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*